GIP and obesity disorder: Multi-agonist peptides that incorporate AMY receptor agonism have also been developed as illustrated by PTT-A, a long-acting tetra-agonist at the GLP-1, GIP, amylin and calcitonin receptors that decreased food intake and body weight in a rat model of obesity [71].